Tokyo, Jan. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060120) titled 'The effectiveness of 19G FNA and 22G FNB needle for diagnosing lymphadenopathy' on Jan. 1.
Study Type:
Observational
Primary Sponsor:
Institute - other
Condition:
Condition - mediastinal or abdominal lymphadenopathy
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the usefulness of 19G FNA and 22G FNB needles for lymphadenopathy diagnosis
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Female
Key inclusion criteria - >17-years-old
EUS-FNA performed cases with mediastinal or abdominal lymphadenopathy using 19G FNA or 22G FNB needle
Key exclusion criteria - Use of needles other than the 19-gauge FNA needle or 22-gauge FNB needle
inability to provide informed consent
The patients who are otherwise judged by the investigator to be ineligible to participate in the study.
Target Size - 200
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 10 Month 17 Day
Date of IRB - 2022 Year 03 Month 01 Day
Anticipated trial start date - 2025 Year 11 Month 16 Day
Last follow-up date - 2027 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068759
Disclaimer: Curated by HT Syndication.
